Herpes simplex virus type 2 and heterosexual spread of human immunodeficiency virus infection in developing countries: Hypotheses and research priorities

Clinical Microbiology and Infection

Volumn 9, Issue 3, 2003, Pages 161-171

  Mbopi Keou, F X ^a,b   Robinson, N J ^c   Mayaud, P ^d   Belec, L ^e   Brown, D W G ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Developing countries; Herpes simplex virus type 2; Human immunodeficiency virus; Intervention

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DISC HERPES SIMPLEX VACCINE; HERPES SIMPLEX VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT GLYCOPROTEIN VACCINE GB2; RECOMBINANT GLYCOPROTEIN VACCINE GD2; THYMIDINE KINASE; UNCLASSIFIED DRUG;

DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; FEMALE; GENITAL ULCER; HEALTH EDUCATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; MEDICAL RESEARCH; MOLECULAR INTERACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SENSITIVITY ANALYSIS; SEROLOGY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; SIMPLEXVIRUS;

EID: 0037366716     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00550.x     Document Type: Review

References (86)

1. Whitley RJ, Roizman B. Herpex simplex virus infections. Lancet 2001; 357: 1513-18.
2. Ashley R, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999; 1: 1-8.
3. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virological characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1997; 333: 770-5.
4. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121: 847-54.
5. Koelle DM, Schomogyi M, Corey L. Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J Infect Dis 2000; 182: 662-70.
6. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having 'asymptomatic' herpes simplex virus type 2 infection. Ann Intern Med 1989; 110: 882-7.
7. Mertz GJ. Epidemiology of genital herpes infections. Infect Dis Clin North Am 1993; 7: 825-39.
8. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116: 197-202.
9. Benedetti J, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131: 14-20.
10. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994; 5: 570-5.
11. Carpenter LM, Kamali A, Ruberantwari A, Malamba SS, Whitworth JAG. Rates of HIV-1 transmission within marriage in rural Uganda in relation with the HIV sero-status of the partners. AIDS 1999; 13: 1083-9.
12. Whitley RJ. Herpes simplex virus infection of women and their off-spring: implication for a developed society. Proc Natl Acad Sci USA 1994; 91: 2441-7.
13. Brown ZA, Selke S, Zeh J et al. The acquisition of Herpes simplex virus infection during pregnancy. N Engl J Med 1997; 337: 509-15.
14. Patel R, Harper DR. Subclinical herpes virus reactivation and latency. Curr Opin Infect Dis 1998; 11: 31-5.
15. Arvin AM, Hensleigh PA, Prober CG et al. Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med 1986; 315: 796-800.
16. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpex simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116: 433-7.
17. Augenbraum M, Feldman J, Chirgwin K et al. Increased genital shedding of Herpex simplex virus type 2 in HIV seropositive women. Ann Intern Med 1995; 11: 845-7.
18. Wald A, Zeh J, Selke S et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342: 842-50.
19. Strauss SE, Savarese B, Tigges M et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993; 167: 1045-52.
20. Griffiths PD. When is sexually transmitted viral disease not an STD? Rev Med Virol 2000; 10: 71-3.
21. Barton IG, Kinghorn GR, Najem S, Al-Omar LS, Potter CW. Incidence of herpes simplex virus types 1 and 2 isolated in patients with herpes genitalis in Sheffield. Br J Ven Dis 1982; 58: 44-7.
22. Vyse AJ, Gay NJ, Slomka MJ et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000; 76: 183-7.
23. Nahmias A, Lee F, Beckman-Nahamias S. Seroepidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis 1990; 69(suppl): 19-36.
24. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316: 1444-9.
25. Fleming DT, McQuillan GM, Johnson RE et al. Herpes simplex type-2 in the United States, 1976-94. N Engl J Med 1997; 337: 1105-11.
26. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321: 7-12.
27. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol 1999; 135: 1393-7.
28. Hook EW, Cannon RO, Nahmias AJ et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992; 165: 251-5.
29. Laga M, Diallo MO, Buve A. Interrelationship of STD and HIV: where are we now? AIDS 1994; 8(suppl): S119-24.
30. Gwanzura L, McFarland W, Alexander D, Burke RL, Katzenstein D. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis 1998; 177: 481-4.
31. Auvert B, Ballard R, Campbell C et al. HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS 2001; 15: 885-98.
32. O'Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. Sex Transm Infect 1999; 75: 377-84.
33. Obasi A, Mosha F, Quigley M et al. Antibodies to HSV-2 as a marker of sexual risk behaviour in rural Tanzania. J Infect Dis 1999; 179: 16-24.
34. Mbopi-Keou FX, Gresenguet G, Mayaud P et al. Interactions between Herpes simplex virus type 2 and HIV infection in African women: opportunities for intervention. J Infect Dis 2000; 182: 1090-6.
35. Wagner HU, Van Dyck E, Roggen E et al. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. Int J STDs AIDS 1994; 5: 332-7.
36. Nahmias AJ, Lee FK, Keyserling HL. The epidemiology of genital herpes. In: Stanberry LR, ed. Genital and neonatal herpes. New York: John Wiley & Sons, 1996: 93-108.
37. Htun Y. Aetiology of genital ulcer disease in a gold mine STD clinic, South Africa 1986-98. Presentation at the WHO/UNAIDS/LSHTM. HSV-2 programmatic research priorities in developing countries. An international workshop, London, 2001.
38. Cowan FM, Johnson AM, Ashley RL, Corey L, Mindel A. Antibody to HSV-2 as a serological marker of sexual lifestyle in populations. BMJ 1994; 309: 1325-9.
39. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
40. Pepin J, Plummer FA, Brunham RC, Piot P, Cameron DW, Ronald AR. The interaction of HIV and other sexually transmitted diseases: an opportunity for intervention. AIDS 1989; 3: 3-9.
41. Cameron D, Padian N. Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases. AIDS 1990; 4(suppl): S99-103.
42. Laga M, Manoka A, Kivuvu M et al. Non-ulcerative sexually transmitted diseases as risk factor for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7: 95-102.
43. Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised trial. Lancet 1995; 346: 530-6.
44. Waver MJ, Sewankambo NK, Serwadda D et al. Control of sexually transmitted diseases for AIDS prevention in Uganda. A randomised community trial. Rakai Study Group. Lancet 1999; 353: 525-35.
45. Holmberg S, Stewart J, Russel G et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988; 259: 1048-50.
46. Dada AJ, Ajayi AO, Diamondstone L, Quinn TC, Blattner WA, Biggar RJ. A serosurvey of Haemophilus ducreyi, syphilis, and Herpes simplex virus type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria. Sex Transm Dis 1998; 5: 237-42.
47. Schacker T, Ryncarz AJ, Goddard J et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1 infected men. JAMA 1998; 280: 61-6.
48. Hayes R, Schulz K, Plummer FA. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-saharan Africa. Am J Trop Med Hyg 1995; 98: 1-8.
49. Cohen MS, Miller WC. Sexually transmitted diseases and human immunodeficiency virus. Int J Infect Dis 1998; 3: 1-4.
50. Ghys P, Fransen K, Diallo MO et al. The association between cervico-vaginal HIV-1 shedding and STDs, immunosuppression, and serum HIV-1 load in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997; 11: F85-93.
51. Mostad SB, Overbaugh J, Devange DM et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350: 922-7.
52. Langeland N, Haarr L, Mhalu F. Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. Int J STDs AIDS 1998; 9: 104-7.
53. Kamya M, Nsubuga P, Grant R, Hellman N. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. Sex Transm Dis 1995; 22: 351-4.
54. Plummer FA, Simonsen JN, Cameron DW et al. Cofactors in male-female sexual transmission of HIV-1. J Infect Dis 1991; 68: 639-54.
55. Mole L, Ripich S, Marjolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176: 766-70.
56. Kucera LS, Leake E, Iyer N, Raben D, Myrvik QN. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Human Retroviruses 1990; 5: 641-7.
57. Heng MCY, Heng SY, Allen SG. Co-infection and synergy of human imunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994; 343: 255-8.
58. Rando RF, Pellett PE, Luciw PA, Bohan CA, Srinivasan A. Transactivation of human immunodeficiency virus by herpesviruses. Oncogene 1987; 1: 13-18.
59. Mosca JD, Bednarik DP, Raj NBK et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus. Proc Natl Acad Sci USA 1987; 84: 7408-12.
60. Ostove JM, Leonard J, Weck KE, Rabson AB, Gendelman HE. Activation of the human immunodeficiency virus by herpes simplex virus type 1. J Virol 1987; 61: 3726-32.
61. Albrecht MA, DeLuca NA, Byrn RA, Schaffer PA, Hammer SM. The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol 1989; 63: 1861-8.
62. Golden MP, Kim S, Hammer SM et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992; 166: 494-9.
63. Keet I, Lee F, Van Grienven G et al. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin Med 1990; 66: 330-3.
64. Kingsley LA, Armstrong J, Rahman A, Ho M, Rinaldo C. No association between herpes simplex virus type-2 seropositivity or anogenital lesions and HIV seroconversion among homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1990; 3: 773-9.
65. Kuiken CL, Van Griensven GJ, de Vroome EM, Coutinho RA. Risk factors and changes in sexual behavior in male homosexuals who seroconverted for human immunodeficiency virus antibodies. Am J Epidemiol 1990; 132: 523-30.
66. Craib KJ, Meddings DR, Strathdee SA et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med 1995; 71: 150-4.
67. Telzak EE, Chiasson MA, Bevier PJ, Stoneburner RL, Castro KG, Jaffe HW. HIV-1 seroconversion in patients with and without genital ulcer disease: a prospective study. Ann Intern Med 1993; 119: 1181-6.
68. Nelson K, Eiumtrakul S, Celentano D et al. The association of herpes simplex virus type 2 (HSV-2), Haemophilus ducreyi, and syphilis with HIV infection in young men in northern Thailand. J AIDS 1997; 16: 293-300.
69. Nopkesorn T, Mock PA, Mastro TD et al. HIV-1 subtype E incidence and sexually transmitted diseases in a cohort of military conscripts in northern Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 372-9.
70. Weiss HA, Buve A, Robinson NJ et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001; 15(suppl 4): S97-108.
71. McFarland W, Gwanzura L, Bassett MT et al. Prevalence and incidence of Herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999; 180: 1459-65.
72. Khambooruang C, Beyrer C, Natpratan C et al. Human immunodeficiency virus infection and self-treatment for sexually transmitted diseases among northern Thai men. Sex Transm Dis 1996; 23: 264-9.
73. Hitchcock P, Fransen L. Preventing HIV infection: lesson from Mwanza and Rakai. Lancet 1999; 353: 513-15.
74. McDermott MR, Brais LJ, Evelegh MJ. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J Gen Virol 1990; 71: 1497-504.
75. Parr EL, Parr MB. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 1997; 71: 8109-15.
76. Posavad CM, Koelle DM, Corey L. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nature 1998; 4: 381-2.
77. Persson E, Eneroth P, Jeansson S. Secretory IgA against herpes simplex virus in cervical secretions. Genitourin Med 1988; 64: 373-7.
78. Merriman H, Woods S, Winter C, Fahnlander A, Corey L. Secretory IgA antibodies in cervicovaginal secretions from women with genital infection due to herpes simplex virus. J Infect Dis 1984; 149: 505-10.
79. Ashley RL, Corey L, Dalessio J et al. Protein-specific antibody responses to primary genital herpes simplex virus type 2 infections. J Infect Dis 1994; 170: 20-6.
80. Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996; 13: 1230-4.
81. Berman PW, Gregory T, Crase D, Lasky LA. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 1985; 227: 1490-2.
82. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987; 155: 914-20.
83. Strauss SE, Rooney JF, Hallahan C. Acyclovir suppresses subclinical shedding of herpes virus. Ann Intern Med 1996; 125: 776.
84. Corey L, Langenberg AG, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - two randomized controlled trials: Chiron HSV Vaccine Study Group. JAMA 1999; 28: 367-79.
85. Spruance SL, SmithKline Beecham (SB) Herpes Vaccine Efficacy Study Group. Gender specific efficacy of a prophylactic SBAS4-adjuvanted γD2 subunit vaccine against genital herpes disease (GHD): results of two clinical efficacy trials [abstract 466]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington, DC: American Society for Microbiology, 2000: p. 263.
86. WHO/UNAIDS/LSHTM. HSV-2 programmatic research priorities in developing countries. An International Workshop, London. Geneva: World Health Organization, 2001.